Andrew N. Schiff, Director at Aclaris Therapeutics, Inc. (ACRS), sold 91,078 shares at $16.54 ($1.5M) on 2022-10-06, disclosed to the SEC on 2022-10-06.
Open-market sale of $1.5M ACRS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.01 | 7,700 | $123K | 8.2% |
| 2 | $16.01 | 7,700 | $123K | 8.2% |
| 3 | $16.54 | 37,839 | $626K | 41.8% |
| 4 | $16.54 | 37,839 | $626K | 41.8% |
| Total | $16.45 avg | 91,078 | $1.5M | 100% |
| Filing → |
| ACRS | SELL | 2022-10-19 | $1.7M | — | Filing → |
| ACRS | SELL | 2022-10-11 | $237K | — | Filing → |
| ACRS | SELL | 2022-06-21 | $592K | — | Filing → |